Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07027488 · ClinicalTrials.gov registry record · Phase 1
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Advanced Melanoma and Advanced Melanoma and Normal or Impaired, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07027488: Recruiting Phase 1 study of Advanced Melanoma and Advanced Melanoma and Normal or Impaired, sponsored by Yale University.
NCT07027488 is a Phase 1 study of Advanced Melanoma and Advanced Melanoma and Normal or Impaired that is actively recruiting participants, run by Yale University. The registered enrollment target is 50 participants, below the 169-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07027488, a Phase 1 study of Advanced Melanoma and Advanced Melanoma and Normal or Impaired, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a first-in-human, open-label, nonrandomized, single center Phase 1 dose-escalation study to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of AB821 monotherapy given every 2 weeks (Q2W) in participants with recurrent locally advanced or metastatic melanoma and other immune-responsive solid tumors. Immune-responsive solid tumors are defined as those for which immune checkpoint inhibitors form part of the standard-of-care therapy.
Primary Outcome
The primary objective of this outcome measure is to assess the number of participants experiencing dose-limiting toxicities (DLTs) during the study period. DLTs are specific adverse events (AEs) that are considered significant enough to prevent an increase in dose or continuation of treatment.
Conditions Studied
Interventions
- DRUG AB821
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-08-05 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT07027488 shows while recruiting
NCT07027488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 169-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Advanced Melanoma appearing as the primary indexed condition, and to 1 intervention - of which AB821 is the first listed.
NCT07027488 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT07027488 about?
NCT07027488 is a clinical study titled "AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors". This study is a first-in-human, open-label, nonrandomized, single center Phase 1 dose-escalation study to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of AB821 monotherapy given every 2 weeks (Q2W) in participants with recurrent locally ad...
What is the current status of trial NCT07027488?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-08-05. Estimated completion is 2027-08.
What conditions does trial NCT07027488 study?
This clinical trial studies the following conditions: Advanced Melanoma, Advanced Melanoma and Normal or Impaired.
What interventions are being tested in trial NCT07027488?
The interventions under investigation include: AB821 (DRUG).
Who is sponsoring clinical trial NCT07027488?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07027488 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07027488's enrollment target sits among peer trials
50 13th of 21 higher than 9 of 21 other Advanced Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
RECRUITING · Phase 1
-
Naltrexone and Propranolol Combined With Immunotherapy
RECRUITING · Phase 1
-
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
RECRUITING · Phase 1
-
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
RECRUITING · Phase 1
-
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI